P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
You may also be interested in...
Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals
Actonel Approved For Male Osteoporosis Indication
The approval brings the Proctor & Gamble/Sanofi-Aventis product in line with competitors.
Actonel Approved For Male Osteoporosis Indication
The approval brings the Proctor & Gamble/Sanofi-Aventis product in line with competitors.